Merck & Co. Inc. (MRK)

$102.95

-1.35

(-1.29%)▲

Market is closed - opens 7 PM, 02 Oct 2023
star icon

Merck & Co Inc is a pharmaceutical company that develops and sells prescription drugs in various therapeutic areas, including oncology, vaccines, and infectious diseases.

Insights on Merck & Co. Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 13.83B → 15.03B (in $), with an average increase of 4.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 6 quarters, 4.31B → -5.97B (in $), with an average decrease of 70.3% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 66.1% return, outperforming this stock by 46.6%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 262.9% return, outperforming this stock by 238.8%

Performance

  • $102.75
    $104.43
    $102.95
    downward going graph

    0.2%

    Downside

    Day's Volatility :1.61%

    Upside

    1.42%

    downward going graph
  • $83.73
    $118.05
    $102.95
    downward going graph

    18.67%

    Downside

    52 Weeks Volatility :29.07%

    Upside

    12.79%

    downward going graph

Returns

PeriodMerck & Co. Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-10.78%
-3.0%
-2.6%
6 Months
-2.8%
0.5%
2.0%
1 Year
19.54%
6.3%
16.6%
3 Years
24.11%
22.1%
20.6%

Highlights

Market Capitalization
264.7B
Book Value
$15.24
Dividend Share
2.84
Dividend Yield
2.8%
Earnings Per Share (EPS)
1.22
PE Ratio
85.49
PEG Ratio
1.36
Wall Street Target Price
124.15
Profit Margin
5.34%
Operating Margin TTM
14.87%
Return On Assets TTM
5.12%
Return On Equity TTM
7.61%
Revenue TTM
58.3B
Revenue Per Share TTM
22.98
Quarterly Revenue Growth YOY
3.0%
Gross Profit TTM
42.1B
EBITDA
12.3B
Diluted Eps TTM
1.22
Quarterly Earnings Growth YOY
-0.35
EPS Estimate Current Year
3.03
EPS Estimate Next Year
8.42
EPS Estimate Current Quarter
-2.18
EPS Estimate Next Quarter
1.95

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 32 Wall street analysts offering stock ratings for Merck & Co. Inc.(by analysts ranked 0 to 5 stars)
Based on 32 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
24
25
24
Hold
8
8
9
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 20.59%

Current $102.95
Target $124.15

Company Financials

FY17Y/Y Change
Revenue
40.1B
↑ 0.79%
Net Income
2.4B
↓ 38.93%
Net Profit Margin
5.97%
↓ 3.88%
FY18Y/Y Change
Revenue
42.3B
↑ 5.41%
Net Income
6.2B
↑ 159.82%
Net Profit Margin
14.71%
↑ 8.74%
FY19Y/Y Change
Revenue
46.8B
↑ 10.75%
Net Income
9.8B
↑ 58.25%
Net Profit Margin
21.01%
↑ 6.3%
FY20Y/Y Change
Revenue
48.0B
↑ 2.46%
Net Income
7.1B
↓ 28.2%
Net Profit Margin
14.72%
↓ 6.29%
FY21Y/Y Change
Revenue
48.7B
↑ 1.48%
Net Income
13.0B
↑ 84.65%
Net Profit Margin
26.79%
↑ 12.07%
FY22Y/Y Change
Revenue
59.3B
↑ 21.72%
Net Income
14.5B
↑ 11.27%
Net Profit Margin
24.49%
↓ 2.3%
Q1 FY22Q/Q Change
Revenue
15.9B
↑ 17.6%
Net Income
4.3B
↑ 14.69%
Net Profit Margin
27.11%
↓ 0.68%
Q2 FY22Q/Q Change
Revenue
14.6B
↓ 8.23%
Net Income
3.9B
↓ 8.49%
Net Profit Margin
27.03%
↓ 0.08%
Q3 FY22Q/Q Change
Revenue
15.0B
↑ 2.51%
Net Income
3.2B
↓ 17.65%
Net Profit Margin
21.71%
↓ 5.32%
Q4 FY22Q/Q Change
Revenue
13.8B
↓ 7.55%
Net Income
3.0B
↓ 7.11%
Net Profit Margin
21.81%
↑ 0.1%
Q1 FY23Q/Q Change
Revenue
14.5B
↑ 4.75%
Net Income
2.8B
↓ 6.5%
Net Profit Margin
19.47%
↓ 2.34%
Q2 FY23Q/Q Change
Revenue
15.0B
↑ 3.78%
Net Income
-6.0B
↓ 311.8%
Net Profit Margin
-39.74%
↓ 59.21%
FY17Y/Y Change
Total Assets
87.9B
↓ 7.87%
Total Liabilities
53.3B
↓ 3.21%
FY18Y/Y Change
Total Assets
82.6B
↓ 5.96%
Total Liabilities
55.8B
↑ 4.6%
FY19Y/Y Change
Total Assets
84.4B
↑ 2.13%
Total Liabilities
58.4B
↑ 4.74%
FY20Y/Y Change
Total Assets
91.6B
↑ 8.52%
Total Liabilities
66.2B
↑ 13.34%
FY21Y/Y Change
Total Assets
105.7B
↑ 15.4%
Total Liabilities
67.4B
↑ 1.89%
Q1 FY22Q/Q Change
Total Assets
106.7B
↑ 0.92%
Total Liabilities
65.7B
↓ 2.55%
Q2 FY22Q/Q Change
Total Assets
107.1B
↑ 0.4%
Total Liabilities
63.8B
↓ 2.95%
Q3 FY22Q/Q Change
Total Assets
107.1B
↓ 0.01%
Total Liabilities
62.6B
↓ 1.91%
Q1 FY23Q/Q Change
Total Assets
99.0B
-
Total Liabilities
52.1B
-
FY17Y/Y Change
Operating Cash Flow
6.4B
↓ 37.87%
Investing Cash Flow
2.7B
↓ 183.46%
Financing Cash Flow
-10.0B
↑ 10.64%
FY18Y/Y Change
Operating Cash Flow
10.9B
↑ 69.41%
Investing Cash Flow
4.3B
↑ 61.03%
Financing Cash Flow
-13.2B
↑ 31.52%
FY19Y/Y Change
Operating Cash Flow
13.4B
↑ 23.05%
Investing Cash Flow
-2.6B
↓ 160.94%
Financing Cash Flow
-8.9B
↓ 32.67%
FY20Y/Y Change
Operating Cash Flow
10.3B
↓ 23.71%
Investing Cash Flow
-9.4B
↑ 259.19%
Financing Cash Flow
-2.8B
↓ 68.04%
FY21Y/Y Change
Operating Cash Flow
14.1B
↑ 37.61%
Investing Cash Flow
-16.4B
↑ 73.9%
Financing Cash Flow
2.6B
↓ 191.56%
FY22Y/Y Change
Operating Cash Flow
19.1B
↑ 35.34%
Investing Cash Flow
-5.0B
↓ 69.79%
Financing Cash Flow
-9.1B
↓ 451.68%
Q1 FY22Q/Q Change
Operating Cash Flow
4.8B
↓ 5.37%
Investing Cash Flow
-1.2B
↓ 90.26%
Financing Cash Flow
-3.1B
↓ 159.27%
Q2 FY22Q/Q Change
Operating Cash Flow
4.3B
↓ 9.64%
Investing Cash Flow
-1.1B
↓ 8.18%
Financing Cash Flow
-1.8B
↓ 42.42%
Q3 FY22Q/Q Change
Operating Cash Flow
5.6B
↑ 30.22%
Investing Cash Flow
-962.0M
↓ 10.68%
Financing Cash Flow
-2.7B
↑ 52.05%
Q4 FY22Q/Q Change
Operating Cash Flow
4.4B
↓ 20.92%
Investing Cash Flow
-1.7B
↑ 81.7%
Financing Cash Flow
-1.6B
↓ 42.49%
Q1 FY23Q/Q Change
Operating Cash Flow
1.3B
↓ 69.77%
Investing Cash Flow
-2.4B
↑ 34.95%
Financing Cash Flow
-2.1B
↑ 32.18%
Q2 FY23Q/Q Change
Operating Cash Flow
3.7B
↑ 176.62%
Investing Cash Flow
-11.4B
↑ 385.08%
Financing Cash Flow
3.8B
↓ 282.96%

Technicals Summary

Sell

Neutral

Buy

Merck & Co. Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Merck & Co. Inc.
Merck & Co. Inc.
-6.59%
-2.8%
19.54%
24.11%
43.93%
Eli Lilly And Company
Eli Lilly And Company
-1.98%
57.66%
66.11%
262.88%
399.19%
Johnson & Johnson
Johnson & Johnson
-4.87%
1.51%
-4.66%
4.61%
11.5%
Abbvie Inc.
Abbvie Inc.
0.5%
-5.61%
11.06%
70.18%
56.91%
Pfizer Inc.
Pfizer Inc.
-7.6%
-17.86%
-24.2%
-9.62%
-25.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Merck & Co. Inc.
Merck & Co. Inc.
85.49
85.49
1.36
3.03
0.08
0.05
0.03
15.24
Eli Lilly And Company
Eli Lilly And Company
75.62
75.62
2.18
9.77
0.66
0.1
0.01
12.3
Johnson & Johnson
Johnson & Johnson
31.82
31.82
3.79
10.03
0.17
0.09
0.03
28.92
Abbvie Inc.
Abbvie Inc.
31.33
31.33
1.28
11.05
0.63
0.09
0.04
7.29
Pfizer Inc.
Pfizer Inc.
8.53
8.53
1.17
3.31
0.23
0.08
0.05
17.54
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$264.7B
43.93%
85.49
5.34%
Eli Lilly And Company
Eli Lilly And Company
Buy
$516.8B
399.19%
75.62
22.01%
Johnson & Johnson
Johnson & Johnson
Hold
$378.3B
11.5%
31.82
13.35%
Abbvie Inc.
Abbvie Inc.
Buy
$268.7B
56.91%
31.33
15.5%
Pfizer Inc.
Pfizer Inc.
Hold
$181.2B
-25.07%
8.53
27.55%

Institutional Holdings

  • Vanguard Group Inc

    9.60%

  • BlackRock Inc

    8.10%

  • State Street Corporation

    4.67%

  • Wellington Management Company LLP

    3.04%

  • Geode Capital Management, LLC

    2.08%

  • Morgan Stanley - Brokerage Accounts

    1.54%

Corporate Announcements

  • Merck & Co. Inc. Dividends March,2023

    In the quarter ending March,2023. Merck & Co. Inc. has declared dividend of $0.73

    Read More

Company Information

Merck & Co., Inc. is an American multinational pharmaceutical company. The corporation conducts business outside of the United States and Canada under Merck Sharp & Dohme (MSD). It was founded as an American subsidiary of the German pharmaceutical company Merck & Co. in 1891. The company was given this name in honour of the Merck family. Merck acquired the Livogen trademark from Glaxo India for Rs 8 crore in 2000 - well over the market value. According to the company, Rofecoxib will be distributed in the Philippines via a co-marketing arrangement with the local pharmaceutical business Kopran. When Biochem Pharmaceutical Industries Ltd purchased Taloja in 2004, the firm spent a total of Rs 100 million, making it the most costly acquisition the company had made then. On March 27, 2002, a decision was made to rename the company from E Merck (India) Ltd to Merck Ltd, and the company was officially constituted on that day. This increased the firm's capacity for the manufacturing of Bulk Drugs by 33 tonnes in 2006, increasing the company's overall production capacity to 351 tonnes. In 2020, the pharmaceutical business will have six blockbuster medications or products with more than $1 billion in revenue. An antibody used to treat cancer is Keytruda, estimated to make $14.3 billion this year. Varivax is supposed to make $3.9 billion each, and Gardasil will make $1.4 billion each. Currently Merck & Co. Inc. has a market cap of $264.66 Billion. It has a P.E ratio of 85.07. The shares of Merck & Co. Inc. are trading at $102.95. .

Organization
Merck & Co. Inc.
Employees
67000
CEO
Mr. Robert M. Davis J.D.
Industry
Health Technology

Discover More

FAQs